These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 35278581)
21. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640 [TBL] [Abstract][Full Text] [Related]
22. A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases. Leonard RA; Rao VN; Bartlett A; Froggatt HM; Luftig MA; Heaton BE; Heaton NS J Virol; 2023 Aug; 97(8):e0059723. PubMed ID: 37578235 [TBL] [Abstract][Full Text] [Related]
23. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Heilmann E; Costacurta F; Geley S; Mogadashi SA; Volland A; Rupp B; Harris RS; von Laer D Commun Biol; 2022 Apr; 5(1):391. PubMed ID: 35478219 [TBL] [Abstract][Full Text] [Related]
24. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity. Stobart CC; Sexton NR; Munjal H; Lu X; Molland KL; Tomar S; Mesecar AD; Denison MR J Virol; 2013 Dec; 87(23):12611-8. PubMed ID: 24027335 [TBL] [Abstract][Full Text] [Related]
25. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds. Zhu J; Zhang H; Lin Q; Lyu J; Lu L; Chen H; Zhang X; Zhang Y; Chen K Drug Des Devel Ther; 2022; 16():1067-1082. PubMed ID: 35450403 [TBL] [Abstract][Full Text] [Related]
26. Fragment-based in silico design of SARS-CoV-2 main protease inhibitors. Ahmad S; Usman Mirza M; Yean Kee L; Nazir M; Abdul Rahman N; Trant JF; Abdullah I Chem Biol Drug Des; 2021 Oct; 98(4):604-619. PubMed ID: 34148292 [TBL] [Abstract][Full Text] [Related]
27. Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and Glaab E; Manoharan GB; Abankwa D J Chem Inf Model; 2021 Aug; 61(8):4082-4096. PubMed ID: 34348021 [TBL] [Abstract][Full Text] [Related]
28. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151 [TBL] [Abstract][Full Text] [Related]
29. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations. Noroozi Tiyoula F; Aryapour H PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108 [TBL] [Abstract][Full Text] [Related]
30. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715 [TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. Moustaqil M; Ollivier E; Chiu HP; Van Tol S; Rudolffi-Soto P; Stevens C; Bhumkar A; Hunter DJB; Freiberg AN; Jacques D; Lee B; Sierecki E; Gambin Y Emerg Microbes Infect; 2021 Dec; 10(1):178-195. PubMed ID: 33372854 [TBL] [Abstract][Full Text] [Related]
32. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation. Bei ZC; Yu H; Wang H; Li Q; Wang B; Zhang D; Xu L; Zhao L; Dong S; Song Y Emerg Microbes Infect; 2023 Dec; 12(1):2211688. PubMed ID: 37144395 [No Abstract] [Full Text] [Related]
33. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening. Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729 [No Abstract] [Full Text] [Related]
34. Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study. Kumar V; Kar S; De P; Roy K; Leszczynski J SAR QSAR Environ Res; 2022 May; 33(5):357-386. PubMed ID: 35380087 [TBL] [Abstract][Full Text] [Related]
38. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Liu H; Iketani S; Zask A; Khanizeman N; Bednarova E; Forouhar F; Fowler B; Hong SJ; Mohri H; Nair MS; Huang Y; Tay NES; Lee S; Karan C; Resnick SJ; Quinn C; Li W; Shion H; Xia X; Daniels JD; Bartolo-Cruz M; Farina M; Rajbhandari P; Jurtschenko C; Lauber MA; McDonald T; Stokes ME; Hurst BL; Rovis T; Chavez A; Ho DD; Stockwell BR Nat Commun; 2022 Apr; 13(1):1891. PubMed ID: 35393402 [TBL] [Abstract][Full Text] [Related]
39. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors. Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913 [TBL] [Abstract][Full Text] [Related]
40. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease]. Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]